Illumina to Announce First Quarter 2010 Financial Results on Wednesday, April 28, 2010
April 14 2010 - 6:00AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue
results for first quarter 2010 following the close of market on
Wednesday, April 28, 2010.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time),
Jay Flatley, president and chief executive officer, and Christian
Henry, senior vice president, chief financial officer and general
manager of Life Sciences, will host a conference call with
analysts, investors, and other interested parties to discuss
financial and operating results.
Conference Call Details:
The conference call will begin at 2:00pm Pacific Time (5:00pm
Eastern Time) on Wednesday, April 28, 2010. Interested parties may
listen to the call by dialing 866.578.5801 (passcode: 41726099), or
if outside North America, by dialing +617.213.8058 (passcode:
41726099). Individuals may access the live teleconference under the
"Corporate/Investor Information" tab of Illumina's web site at
www.illumina.com.
A replay of the conference call will be available from 5:00pm
Pacific Time (8:00pm Eastern Time) on April 28, 2010, through May
5, 2010, by dialing 888.286.8010, or if outside North America, by
dialing +1.617.801.6888 (passcode: 52772593).
About Illumina
Illumina (http://www.illumina.com) is a leading developer,
manufacturer, and marketer of life-science tools and integrated
systems for the large-scale analysis of genetic variation and
biological function. Using our proprietary technologies, we provide
a comprehensive line of products and services that currently serve
the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers
include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the
world with the performance, throughput, cost effectiveness, and
flexibility necessary to perform the billions of genetic tests
needed to extract valuable medical information from advances in
genomics and proteomics. We believe this information will enable
researchers to correlate genetic variation and biological function,
which will enhance drug discovery and clinical research, allow
diseases to be detected earlier, and permit better choices of drugs
for individual patients.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jul 2023 to Jul 2024